Background
==========

In the surgical treatment of benign bone tumours, intralesional curettage has been performed throughout the past century. Over the recent years, **its**use has been extended to low-grade intramedullary malignant tumours in some instances. Unfortunately, this surgical technique has the risk of local recurrence from tumour cells that may be left behind. For this reason curettage was supplemented by the use of a local adjuvant, such as phenol, liquid nitrogen or bone cement (poly methyl methacrylate, PMMA). Various studies have demonstrated that by using adjuvant, the results of local therapy have been greatly improved \[[@B1]-[@B4]\].

With regard to liquefied phenol, only a few documented studies have been published, despite of **its**routine use over a long period in orthopaedic practice. Previously, we were able to show that in case of low-grade chondrosarcoma, phenol is able to kill tumour cells *in-vitro*already at a concentration of 3% \[[@B5]\]. In clinical settings, liquefied phenol is known to reduce local recurrence rates in different benign bone tumours such as aneurysmal bone cysts, chondroblastoma and giant cell tumours from **41% to 7-9%**\[[@B1],[@B2]\]. Liquefied phenol, containing 82.0 to 86.5% w/w phenol in water, is a colourless or faintly coloured liquid. It may be used as a preservative in pharmaceuticals and chemicals, but is also widely used in household products. Liquefied phenol is readily absorbed via inhalation, ingestion and dermal contact, causing both local and systemic toxicity. The elimination half-life ranges from 1-14 hours \[[@B6]\]. It is eliminated in the urine, mainly as sulfate and glucuronide conjugates. Liquefied phenol causes cell-wall disruption, precipitation, denaturation of proteins and coagulation necrosis. Aqueous solutions as dilute as 10% may be corrosive.

Clinical symptoms of phenol after ingestion may include local corrosion with pain, nausea, vomiting and diarrhea \[[@B6]\]. Systemic toxicity may consist of CNS depression, circulatory and respiratory failure, pulmonary edema and hepatic and renal injury. Poisoning may occur from skin contact, especially from wounds. Applied to the skin, phenol causes blanching and corrosion in a concentration of 1-2%, depending on the exposure time.

In case of surgery, a bone-window is created in order to perform a subsequent curettage of the tumour. To ensure that the cavity that has been formed is microscopically tumour-free, the walls are cauterised with an 85% solution of liquefied phenol. Given that liquefied phenol has toxic and potentially carcinogenic properties when used systemically over a longer period, the cavity is then rinsed a number of times with a 96% solution of ethanol. The cavity is filled with allograft bone-chips and the bone-window, which has also been rinsed with liquefied phenol and ethanol, is placed back in position. The above mentioned surgical technique has our preference given its advantage to induce minimal local damage and a biological reconstruction. Alternative products to fill the resultant defect after curettage are PMMA, auto graft bone chips or synthetic bone materials.

Regarding the surgical technique, some questions remain:

1\. What is the initial local concentration of phenol in the tissue of the cavity wall after the application of liquefied phenol 85%?

2\. How quickly is the liquefied phenol 85% diluted by washing the bone cavity with ethanol 96% solution?

3\. Is the degree and speed of dilution influenced by the size of the cavity?

4\. How many times should the cavity be rinsed to obtain sufficient elimination of phenol?

Answering these questions will further elucidate the safe practice of phenol-assisted, intralesional curettage of low grade malignant intramedullary bone tumours.

Patients and methods
====================

Patients
--------

16 patients (5 male, 11 female) with a median age of 48 (range 26-70) at time of surgery, were treated for grade I chondrosarcoma. The tumours are predominantly located in the proximal humerus (7/16, 44%) and the distal femur (5/16, 31%) (Table [1](#T1){ref-type="table"}). The lesions were histologically classified by an experienced pathologist according to the recently published consensus criteria \[[@B7]\] and graded according to the Evans\' grading \[[@B8]\].

###### 

Patient information, tumour volume and cavity surface

  Patient   Age/Gender   PA       Location           Tumour volume (cm3)   Cavity surface (cm2)
  --------- ------------ -------- ------------------ --------------------- ----------------------
  1         41/M         CHS I    Proximal humerus   27                    73,4
  2         39/M         CHS I    Distal femur       48,1                  74,2
  3         40/F         CHS I    Distal tibia       9,2                   24,6
  4         411 M        CHS I    Proximal humerus   26,3                  62,3
  *5*       *45/F*       CHS I    Proximal humerus   40,8                  72,6
  6         70ff         CHS I    Distal femur       10,9                  62,3
  7         *55/M*       CHS I    Distal femur       39,4                  74,6
  8         59/F         CHS I    Proximalhumerus    14,7                  33,4
  9         49/F         CHS II   Proximal humerus   9,7                   25,8
  10        48/F         CHS I    Distal femur       33                    58,8
  11        67/F         CHS I    Distal tibia       *5,2*                 16,8
  12        44/F         CHS I    Proximal humerus   25,8                  49,4
  13        33/NI        CHS I    Metacarpal         V 4,4                 15,3
  14        50/F         CHS I    Humerus            44                    74,5
  *15*      *55/F*       CHS I    Proximal humerus   32                    *59,3*
  16        26/F         CHS I    Distal femur       20                    *51,5*

Characteristics of the 16 patients where the tests during surgery were performed. Depending on the location of the chondrosarcoma, the cavity surface varies.

Clinical setting
----------------

Following a trial on three patients to test the feasibility of the study, 16 patients, suspected with grade I chondrosarcoma following X-ray and dynamic Gd-MRI \[[@B9]\], were treated according to the surgical technique described above. Two tests were performed. Test 1 was done on all 16 patients, test 2 on 10 patients. Before performing surgery including these tests, all patients were informed and gave their approval. Patient material was used in a coded fashion according to the local ethical regulation and in accordance to the national ethical guidelines (Dutch organisation of scientific societies FEDERA; \"Code for proper secondary use of human tissue\" in the Netherlands).

Treatment protocol
------------------

### Test 1

Depending on the size of the cavity, 2 to 4 ml of liquefied phenol 85% was applied with one or more small gauzes at the inner surface of the wall for 3 minutes after curettage of the bone tumour. Then the cavity was filled with an ethanol 96% solution. The volume of ethanol differed depending on the size of the cavity. Subsequently, this mixture of phenol and ethanol was extracted by syringe and sealed immediately in a polypropylene container. This procedure was repeated ten times and labelled accordingly (sample numbers I to X).

### Test 2

During surgery two biopsies were taken. The first biopsy (A)was taken after the cavity had been swabbed with the 85% phenol solution. A second biopsy (B) was taken after the cavity had been rinsed thoroughly ten times with ethanol, as described above (Table [2](#T2){ref-type="table"}).

###### 

Concentrations of phenol in sixteen patients during washing out phenol with ethanol

         1     2      3      4      5      6       7     8      9      10     11     12     13      14     15    16
  ------ ----- ------ ------ ------ ------ ------- ----- ------ ------ ------ ------ ------ ------- ------ ----- -----
  I      929   2435   8032   3264   9661   13000   289   1300   1500   1500   1500   2299   20974   1239   373   160
  II     449   900    2889   730    1780   563     193   787    734    1500   1478   816    13932   889    247   118
  III    177   469    2169   293    1097   201     555   473    329    539    1199   523    4652    644    159   97
  IV     92    313    1019   83     944    119     156   418    249    195    495    292    1739    465    82    66
  V      84    185    797    106    632    162     167   313    150    160    185    261    1932    407    77    89
  VI     69    189    522    73     312    126     146   289    127    87     249    223    1287    307    82    54
  VII    65    128    400    49     168    101     98    191    97     126    157    160    805     214    65    64
  VIII   65    146    381    72     227    72      114   126    97     116    217    140    900     215    65    39
  IX     42    325    294    59     392    138     52    124    110    57     178    111    597     162    87    42
  X      105   217    279    47     200    54      64    98     88     60     143    117    417     182    60    29

Results of 16 patients (1-16); after using phenol 85% as adjuvant therapy, ethanol 96% was used to wash out the phenol; sample I to X show ppm of phenol in ethanol; Note that the bold results are not reliable or higher measured level than in reality.

These biopsies (A and B), plus the ten flush solutions (I to X) were then further investigated to determine the concentration of phenol.

The surface area of the cavity
------------------------------

It is necessary to approximate the shape of the cavity, because the actual surface area does not fit in any standard mathematical model and therefore cannot be measured with absolute precision. Therefore we projected a cylinder over the lesion using the largest diameter of the cartilaginous tumour of the long bones, measured in three dimensions on the pre-operative MRI. A standard formula was used to calculate the inner surface of this cylindrical curetted bone cavity: *2 πr (r + h). R*represents the average of half the width (mediolateral) and half the depth (anteroposterior), which often corresponds with the inside diameter of the bone. *H*is the length of the tumour taken in a craniocaudal direction.

Sampling
--------

The flush solutions, from test 1, and the bone biopsies, from test 2, were stored in a refrigerator until analysis. Flush solutions were analyzed as such, or after dilution (see phenol analysis). Bone biopsies were dispersed in 5.0 ml ethanol 96% v/v; an aliquot of this solution was analyzed.

Phenol analysis
---------------

The phenol concentration of the ethanolic flush solutions was determined by High Performance Liquid Chromatography (HPLC) with spectrophotometric detection. Briefly, chromatographic analysis of the samples (diluted with ethanol to fit within the concentration range of the calibration curve, if necessary) was performed on a silica reversed phase column (Nucleosil C18, 100 × 3 mm, 5 μm particle size) with a mobile phase consisting of 25 mM phosphate buffer containing 0,5% triethylamine pH 3.0 and acetonitrile (83 + 17, v/v). The column flow rate was 0.4 ml/min and detection was performed at 212 nm. The injection volume was 10 μl. The phenol concentrations in the flush solutions were calculated from calibration graphs obtained by simultaneous analysis of phenol standard solutions in ethanol 96% v/v in the concentration range 30 - 1500 ppm phenol. Up to 500 ppm there was a linear relation between response and concentration; above 500 ppm a quadratic function had to be used. Inter-day reproducibility showed a coefficient of variation of 5.1% at a concentration level of 50 ppm and 10.6% at 5 ppm (n = 6). The lower limit of quantitation (LLOQ) was 5 ppm. Basic descriptive statistics were employed.

Results
=======

Test 1
------

The phenol concentrations measured in the flush solutions ranged from 29 to 20974 ppm. Large inter-patient differences were observed. Figure [1](#F1){ref-type="fig"} shows a graphical presentation of the decay in phenol concentration over time observed for each patient, expressed as a percentage of the concentration measured in the first flush sample.

![**Concentrations of phenol in ethanol**. Results of ten samples of ethanol with phenol in 16 patients; samples II to X are reproduced as the fraction of the phenol concentration, measured in the first sample.](2045-3329-2-10-1){#F1}

After washing the bone cavity five times with ethanol 96%, in most of the patients the phenol levels measured are \< 280 ppm.

Patient number 7 has one very high concentration of phenol in sample III (Table [2](#T2){ref-type="table"}). We can only explain this as a sample error, because from sample IV to X the concentration decreases.

Test 2
------

In Table [3](#T3){ref-type="table"} the phenol concentrations found in the biopsies, dispersed in 5 ml. ethanol, are presented. For all patients the phenol concentration before (A) and after flushing the cavity with ethanol 96% (B) is shown. Remarkable differences were measured, quantative as well as in reducing the concentration of phenol washed out by ethanol.

###### 

Concentrations of phenol solved in 5 ml. of ethanol during surgery

                   8      9     10    11    12     13   14    15   16
  ---------------- ------ ----- ----- ----- ------ ---- ----- ---- -----
  biopsy A (ppm)   1598   888   168   479   1043   25   572   94   144
  biopsy B (ppm)   408    418   39    106   636    17   587   11   18

Results of phenol samples 9 patients (8-16); first bone biopsy (A) was taken after application phenol 85%. After washing ten times with ethanol 85% the second biopsy (B) was performed. **The concentrations of phenol (ppm) in this table are solved in 5 ml. of ethanol**.

Tumour volume
-------------

Median volume of the cavity is 24.4 cm3 (range 4-48), and depends on the location of the tumour. The smallest volumes are measured in the distal tibia and fifth metacarpal bone.

No correlation is seen between the concentrations of phenol in ethanol in large or small cavities (Figure [2](#F2){ref-type="fig"}).

![**Box Plot of concentration phenol and surface of bone cavity**. Relation between concentrations of phenol measured in ethanol (ppm) and surface of the bone cavity. No correlation is seen between the concentrations of phenol in ethanol in large or small cavities.](2045-3329-2-10-2){#F2}

Discussion
==========

The use of chemical cauterization for benign and low-grade malign bone tumours was first proposed by Bloodgood \[[@B10]\]. Although phenol is used for many years as adjuvant therapy in the intralesional treatment of benign and low-grade malignant bone tumours, no information is available about the local concentration of phenol in individuals, the most sufficient and safest procedure to wash out the phenol after the local use.

Some surgeons have a dislike to the use of phenol as adjuvant, due to the possible predisposition to infection, the inhibition of the incorporation of grafts, systemic toxic effects on patients, and possible adverse effects on personnel in the operating theatre.

In our opinion, the highest estimated risk for using phenol is the people who work with it in the operating room. To prevent skin contact, using the routine measures such as by wearing proper protection to hands and face is sufficient. In case of skin contact, the skin should be irrigated with polyethylene glycol (PEG) 400 solution, isopropanol 70% or, if not available, with water \[[@B10]-[@B14]\]. During surgery, there is a risk of fire, with the evaporation of ethanol and simultaneous use of electric cauterization devices, as this can cause a spark. Therefore, we strongly recommend disconnecting the electric devices from the moment phenol and ethanol bottles are to be opened.

The two biopsies A and B were taken from the cavity wall before starting washing out and after rinsing 10 times with ethanol 96%. In biopsy B, the quantity of phenol is diminished, as expected, but still there is quite a concentration left. This is due to the fact, that phenol is very lipophylic and therefore not easy to remove with ethanol 96%. The results also show remarkable differences in a quantative way. In these patients, tumour volume, differences in dilution by wound fluid and blood in the cavity, and differences in the ml of phenol applicated explain these results. **In patient 14, the concentration even increases a little bit after washing out with ethanol. In this patient, it seems that it is hard to wash out the local phenol from the cavity wall**.

Concerning the initial local concentration of phenol in the cavity wall after application of phenol, two biopsies were curetted. Test 2 shows the concentrations in biopsy A and B. Starting with 85% of liquefied phenol, the mean initial local concentration of phenol measured was 557 ppm (range 25-1598, biopsy A, Table [3](#T3){ref-type="table"}). The measurements have a large variation.

Patient 13 suffered from a small chondrosarcoma of the metacarpal bone. The volume of the tumour was 4,4 cm^3^. Biopsy A and B show 25 and 17 ppm phenol respectively. Nevertheless, the first sample in test 1 has a very high concentration of phenol in ethanol, 20974 ppm. The possible explanation of these controversial measurements is, that the location where the biopsy A and B were taken from the metacarpal bone can almost only be cortical border of the tumour. As cortical bone won\'t absorb phenol very well, the concentrations in biopsy A and B are low.

To investigate the effect of ethanol to dilute the applicated phenol, 10 samples in 16 patients were collected. In test 1, in all 16 cases the highest concentration of phenol was measured in the first sample. However, the absolute values differ. Despite the fact that the same procedure was performed in all cases, no procedure is the same given the different volumes of the tumours varying from 4 to 48 cm^3^. In patient number seven, the III^rd^sample shows an increase of the concentration phenol. From the IV^th^sample, the line decrease further on sample II. The III^rd^sample must be considered to be a sample error. In these tests, the cavity was filled with ethanol ten times, and phenol concentrations were measured. After washing the cavity 6 times, in 10 of 16 patients the fraction of the initial concentration of phenol is \< 10%. The quantative concentration of phenol is \< 1300 ppm in all cases, which means an estimated concentration of phenol of \< 0,2%.

The degree of dilution is not influenced by the size of the cavity after curettage. However, it is remarkable that the highest concentrations in the first samples of test 1 all concerned small tumour volumes. This can be explained by the relatively small volume of ethanol where the phenol is diluted in.

We did not specifically study systemic effects of phenol exposure in our patients; however, on retrospective review, no adverse effects or secondary malignancies were noted.

In the few studies that described measurements of phenol, this was done by taking samples of urine, as liquefied phenol is eliminated by the kidneys. However, it is hard to define a \'thresh hold\' for the toxic level.

This study shows that the adverse effects on the whole body due to the use of liquefied phenol as adjuvant in the intralesional curettage of benign and low-grade malignant bone tumours are reduced to safe concentrations by washing phenol out by ethanol. Phenol is a safe adjuvant when used in a proper way, taking the above mentioned statements into account. Washing the cavity six times with ethanol 96% will be sufficient to diminish the local concentration of liquefied phenol to an acceptable concentration of \< 0.2%.
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